

## Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Diffuse Large B-Cell Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. According to safety data from the Phase II LOTIS-2 trial, which of the following Grade  $\geq 3$  adverse events was most common after treatment with loncastuximab tesirine?**
  - a. Nausea
  - b. Neutropenia**
  - c. Anemia
  - d. Edema
- 2. Based on the results of the TRANSFORM and ZUMA-7 studies, which of the following treatments affected patient survival compared to the standard of care (SOC)?**
  - a. Neither lisocabtagene maraleucel (liso-cel) nor axicabtagene ciloleucel (axi-cel) improved patient survival compared to the SOC
  - b. Only liso-cel improved patient survival compared to the SOC
  - c. Only axi-cel improved patient survival compared to the SOC
  - d. Both liso-cel and axi-cel improved patient survival compared to the SOC**
- 3. According to the results of the Phase III POLARIX trial, what was the progression-free survival rate for patients who received polatuzumab vedotin/R-CHP?**
  - a. Higher than 90%
  - b. Between 70% and 90%**
  - c. Between 50% and 70%
  - d. Lower than 50%
- 4. Which of the following treatments best describes the mechanism of action of tafasitamab?**
  - a. Anti-CD19 monoclonal antibody**
  - b. Cytotoxic chemotherapy
  - c. Chimeric antigen receptor T-cell mediated therapy
  - d. Bispecific antibody
- 5. Cytokine release syndrome is most commonly associated with which of the following treatments?**
  - a. Radiotherapy
  - b. Chemotherapy
  - c. Antibody-drug conjugate therapy
  - d. Bispecific antibody therapy**